Hematological consequences of EB19 infection;L'érythrovirus B19 en hématologie

Hematologie

Volumn 9, Issue 5, 2003, Pages 389-401

  Cohen, Patrick ^a   Guillet, Benoît ^a   Tchernia, Gil ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

B19; Bloodborne viral infections; Human parvovirus; Immunoeficiency; Immunoglobulin; Pure red cell aplasia

Indexed keywords

ANTIGEN; CELL RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; P ANTIGEN; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ANEMIA; ARTHROPATHY; AUTOIMMUNITY; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CHRONIC ARTHRITIS; CHRONIC DISEASE; CYTOLYSIS; CYTOTOXICITY; ERYTHEMA INFECTIOSUM; ERYTHROBLASTOPENIA; ERYTHROID CELL; FETOMATERNAL TRANSFUSION; FETUS DEATH; FETUS HYDROPS; HEMOLYSIS; HEMOLYTIC ANEMIA; HEMOPHILIA; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INTRAUTERINE INFECTION; ORGAN TRANSPLANTATION; PARVOVIRUS; POLYMERASE CHAIN REACTION; PREGNANCY; PURE RED CELL ANEMIA; RESPIRATORY SYSTEM; REVIEW; SERODIAGNOSIS; SKIN MANIFESTATION; VIRAL CONTAMINATION; VIREMIA; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 0346101673     PISSN: 12647527     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Cossart YE, Field AM, Cant B, Widdows D. Parvovirus like particles in human sera. Lancet 1975; i: 72-3.
2. Couroucé AM, Ferchal F, Morinet F, et al. Parvovirus (SPLV) et antigène Aurillac. Étude de 18 observations. Rev Fr Transf Immuno-Hematol 1984; 27: 5-19.
3. Pattison JR, Jones SE, Hodgson J, Davis LR, White JM, Stroud CE, Murtaza L. Parvovirus infections and hypoplastic crisis in sickle-cell anaemia. Lancet 1981; i: 664-5.
4. Anderson MJ, Jones SE, Fisher-Hoch SP, Lewis E, Hall SM, Bartlett CLR, Cohen BJ, Mortimer PP, Pereira MS. Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet 1983; i: 1378.
5. Brown T, Anand A, Ritchie LD, Clewley JP, Reid TMS. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet 1984; ii: 1033-4.
6. Kurtzman GJ, Ozawa K, Cohen BJ, Hanson G, Oseas R, Young NS. Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med 1987; 317: 287-94.
7. Reid DM, Reid TMS, Brown T, Rennie JAM, Brown T, Eastmond CJ. Human parvovirus associated arthritis: a clinical and laboratory description. Lancet 1985; i: 422-5.
8. Nguyen QT, Sifer C, Schneider V, Allaume X, Servant A, Bernaudin F, Auguste V, Garbarg-Chenon A. Novel human Erythrovirus associated with transient aplastic anaemia. J Clin Microbiol 1999; 37: 2483-7.
9. Ozawa K, Ayub J, Young N. Translational regulation of B19 parvovirus capsid protein production by multiple upstream AUG triplets. J Biol Chem 1988; 263: 10922-6.
10. Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993; 262: 114-7.
11. Takahashi T, Ozawa K, Takahashi K, Asano S, Takaku F. Susceptibility of human erythropoietic cells to B19 parvovirus in vitro increases with differentiation. Blood 1990; 75: 603-10.
12. Moffatt S, Yaegashi N, Tada K, Tanaka N, Sugamura K. Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol 1998; 72: 3018-28.
13. Pillet S, Morinet F. Parvovirus and erythroid cells. Pathol Biol 2002; 50: 349-56.
14. Ozawa K, Ayub J, Kajikaya T, Shimada T, Young NS. The gene encoding the non structural protein of B19 (human) parvovirus may be lethal in transfected cells. J Virol 1988; 62: 2884-9.
15. Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988; 25: 151-3.
16. McOmish F, Yap PL, Jordan A, Hart H, Cohen BJ, Simmonds P. Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J Clin Microbiol 1993; 31: 323-8.
17. Lyon DJ, Chapman CS, Martin C. Symptomatic parvovirus B19 infection and heat-treated factor IX concentrate. Lancet 1989; i: 1085.
18. Lefrère JJ, Mariotti M, Thauvin M. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates. Lancet 1994; 343: 211-2.
19. Grossebley A, Eishubinger AM, Kaiser R, Oldenburg J, Brackmann HH, Schwarz TF, Schneweis KE. Serological and virological markers of human parvovirus B19 infection in sera of haemophiliacs. Thromb Haemost 1994; 72: 503-7.
20. Laurian Y, Dussaix E, Parquet A, Chalvon-Demersay A, d'Oiron R, Tchernia G. Transmission of human parvovirus B19 by plasma derivated factor VIII concentrates. Nouv Rev Fr Hématol 1994; 36: 449-53.
21. Eis-Hubinger AM, Oldenburg J, Brackmann HH, Matz B, Schneweis KE. The prevalence of antibody to parvovirus B 19 in haemophiliacs and the general population. Intern J Med Microbiol 1996; 284: 232-40.
22. Rubinstein R, Karabus CD, Smuts H, Kolia F, Van Rensburgs EJ. Prevalence of human parvovirus B19 and TT virus in a group of young haemophiliacs in South Africa. Haemophilia 2000; 6: 93-7.
23. Rollag H, Patou G, Pattison JR, Degre M, Evensen SA, Froland SS, Glomstein A. Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools. Scand J Infect Dis 1991; 23: 675-9.
24. Ragni MV, Koch WC, Jordan JA. Parvovirus B 19 infection in patients with hemophilia. Transfusion 1996; 36: 238-41.
25. Morfini M, Longo G, Rossi-Ferrini P, Azzi A, Zakrewska C, Ciappi S, Kolumban P. Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: the role of human B19 parvovirus. Am J Hematol 1992; 39: 149-50.
26. Yee TT, Lee CA, Pasi KJ. Life-threatening human parvovirus B 19 infection in immunocompetent haemophilia. Lancet 1995; 345: 794-5.
27. Saldanha J, Minor P. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol 1996; 93: 714-9.
28. Lefrère JJ, Mariotti M, De La Croix I, Lerable J, Thauvin M, Burnouf T, Folléa G. Albumin batches and B19 parvovirus DNA. Transfusion 1995; 35: 389-91.
29. Gaboulaud V, Parquet A, Tahiri C, Claeyssens S, Potard V, Faradji A, Peynet J, Costagliola D for the Suivi Thérapeutique National des Hémophies. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort. Br J Haematol 2002; 116: 383-9.
30. Bell LM, Naides SJ, Stoffman P, Hodinka RL, Plotkin SA. Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med 1989; 321: 485-91.
31. Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, Pattison JR, Tyrrell DA. Experimental parvoviral infection in humans. J Infect Dis 1985; 152: 257-65.
32. Woolf AD, Campion GV, Chishick A, Wise S, Cohen BJ, Klouda PT, Caul EO, Dieppe PA. Clinical manifestations of human parvovirus B 19 in adults. Arch Intern Med 1989; 149: 1153-6.
33. Modrow S, Dorsch S. Antibody responses in parvovirus B19 infected patients. Pathol Biol2002; 50: 326-31.
34. Lefrère JJ, Couroucé AM, Bertrand Y, Girot R, Soulier JP. Human parvovirus and aplastic crisis in chronic hemolytic anemias: a study of 24 observations. Am J Hematol 1986; 23: 271-5.
35. Lefrère JJ, Couroucé AM, Girot R, Bertrand Y, Soulier JP. Six cases of hereditary spherocytosis revealed by human parvovirus infection. Br J Haematol 1986; 62: 653-8.
36. Mabin D, Chowdhury V. Aplastic crisis caused by human parvovirus in two patients with hereditary stomatocytosis. Br J Haematol 1990; 76: 153-4.
37. Duncan JR, Potter CG, Cappelini MD, Kurtz JB, Anderson MJ, Weatherall DJ. Aplastic crisis due to parvovirus infection in pyruvate kinase deficiency. Lancet 1983; ii: 14-6.
38. Serjeant BE, Hambleton IR, Kerr S, Kilty CG, Serjeant GR. Haematological response to parvovirus B 19 infection in homozygous sickle-cell disease. Lancet 2001; 358: 1779-80.
39. Bertrand Y, Lefrère JJ, Leverger G. Autoimmune haemolytic anaemia revealed by human parvovirus linked erythroblastopenia. Lancet 1985; ii: 382-3.
40. Tchernia G, Morinet F, Congard B, Croisille L. Diamond Blackfan anaemia: apparent relapse due to B19 parvovirus. Eur J Pediatr 1993; 152: 209-10.
41. Anderson LJ, Hurwitz ES. Human parvovirus B19 and pregnancy. Clin Perinatol 1988; 15: 273-86.
42. Sheikh AU, Ernest JM. Clinical picture and consequences of fetal parvovirus B 19 infection. Ann Med 1995; 27: 7-8.
43. Rogers BB, Singer DB, Mak SK, Gary GW, Fikrig MK, McMillan PN. Detection of human parvovirus B19 in early spontaneous abortuses using serology, histology, electron microscopy, in situ hybridization, and the polymerase chain reaction. Obstet Gynecol 1993; 81: 402-8.
44. Public Health Laboratory Service Working Party on Fifth Disease. Prospective study of human parvovirus B 19 infection in pregnancy. Br Med J 1990; 300: 1166-70.
45. Jensen IP, Thorsen P, Jeune B, Moller BR, Vestergaard BF. An epidemic of parvovirus B19 in a population of 3,596 pregnant women: a study of sociodemographic and medical risk factors. Br J Obstet Gynaecol 2000; 107: 637-43.
46. Morey AL, Keeling JW, Porter HJ, Fleming KA. Clinical and histopathological features of parvovirus infection in the human fetus. Br J Obstet Gynecol 1992; 99: 566-74.
47. Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red cell aplasia of 10 years duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989; 321: 519-23.
48. Hasle H, Kerndrup G, Jacobsen BB, Heegaard ED, Hornsleth A, Lillevang ST. Chronic parvovirus infection mimicking myelodysplastic syndrome in a child with subclinical immunodeficiency. Am J Pediatr Hematol Oncol 1994; 16: 329-33.
49. Baurmann H, Schwarz TF, Oertel J, Serke S, Roggendorf M, Huhn D. Acute parvovirus B19 infection mimicking myelodysplastic syndrome of the bone marrow. Ann Hematol 1992; 64: 43-5.
50. Kurtzman GJ, Ozawa K, Cohen B, Hanson G, Oseas R, Young NS. Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med 1987; 317: 287-94.
51. Geetha D, Zachary JB, Baldado HM, Kronz JD, Krauss ES. Pure red cell aplasia caused by parvovirus B 19 infection in solid organ transplant recipients: a case report and review of literature. Clin Transplant 2000; 14: 586-91.
52. Zolnourian ZR, Curran MD, Rima BK, Coyle PV, O'Neil HJ, Middleton D. Parvovirus B19 in kidney transplant patients. Transplantation 2000; 69: 2198-202.
53. Schowengerdt KO, Ni J, Denfield SW, Gajarski RJ, Radovancevic B, Frazier HO, Demmler GJ, Kearney D, Bricker JT, Towbin JA. Diagnosis, surveillance, and epidemiologic evaluation of viral infections in pediatric cardiac transplant recipients with the use of polymerase chain reaction. J Heart Lung Transplant 1996; 15: 111-23.
54. Schowengerdt KO, Ni J, Denfield SW, Gajarski RJ, Bowles NE, Rosenthal G, Kearney DL, Price JK, Rogers BB, Schauer GM, Chinnock RE, Towbin JA. Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction. Circulation 1997; 96: 3549-54.
55. Ang HA, Apperley JF, Ward KN. Persistence of antibody to human parvovirus B 19 after allogenic bone marrow transplantation: role of prior recipient immunity. Blood 1997; 89: 4646-51.
56. Soderlund M, Ruutu P, Ruutu T, Asikainen K, Franssila R, Hedman K. Primary and secondary infections by human parvovirus B 19 following bone marrow transplantation: characterization by PCR and B-cell molecular immunology. Scand J Infect Dis 1997; 29: 129-35.
57. Broliden K, Tolfvenstam T, Ohlsson S, Henter JI. Persistent B19 parvovirus infection in pediatric malignancies. Med Pediatr Oncol 1998; 31: 66-72.
58. Heegaard ED, Laub Petersen B. Parvovirus B19 transmitted by bone marrow. Br J Hematol 2000; 111: 659-61.
59. Schleuning M, Jäger G, Holler E, Hill W, Thomssen C, Denzlinger C, Lorenz T, Ledderose G, Wilmanns W, Kolb HJ. Human parvovirus B19 associated disease in bone marrow transplantation. Infection 1999; 27: 114-7.
60. Kurtzman G, Cohen B, Meyers P, Amunullah A, Young NS. Persistent B 19 parvovirus infection as a cause of severe chronic anemia in children with acute lymphocytic leukaemia. Lancet 1988; ii: 1159-62.
61. Coulombel L, Morinet F, Miélot F, Tchernia G. Parvovirus infection, leukaemia and immunodeficiency. Lancet 1989; i: 101-2.
62. Aguiar FS, Lopes DP, Bazin AR, Sebutal S, Cohen BJ, Nascimento JP. Human parvovirus B19 infection in VIH-positive patients. Rev Soc Bras Med Trop 2001; 34: 239-42.
63. Söderlund-Venermo M, Hokynar K, Nieminen J, Rautakorpi H, Hedman K. Persistence of parvovirus B19 in human tissues. Pathol Biol 2002; 50: 307-16.
64. Notari EP, Orton SL, Cable RG, Grindon AJ, Lenes BA, Williams AE, McMillan KM, Trouern-Trend JJ, Wolf-Nugent JS, Xu YL, Dodd RY. Seroprevalence of known and putative hepatitis markers in United States blood donors with ALT levels at least 120 IU per L. Transfusion 2001; 41: 751-5.
65. Hillingso JG, Jensen IP, Tom-Petersen L. Parvovirus B19 and acute hepatitis in adults. Lancet 1998; 351: 655-6.
66. Sokal EM, Melchior M, Cornu C, Vandenbroucke AT, Buts JP, Cohen BJ, Burtonboy G. Acute parvovirus infection associated with fulminant hepatitis of favourable prognosis in young children. Lancet 1998; 352: 1739-41.
67. Dame C, Hasan C, Bode U, Eis-Hübinger AM. Acute liver disease and aplastic anemia associated with the persistence of B19 DNA in liver and bone marrow. Pediatr Pathol Mol Med 2002; 21: 25-9.
68. Cassinotti P, Burtonboy G, Fopp M, Siegl G. Evidence for persistence of human parvovirus B 19 DNA in bone marrow. J Med Virol 1997; 53: 229-32.
69. Söderlund M, von Essen R, Haapasaari J, Kiistala U, Kiviluoto O, Hedman K. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997; 349: 1063-5.
70. Naides SJ, Karetnyi YV, Cooling LW, Markin RS, Langnas AN. Human parvovirus B19 infection and hepatitis. Lancet 1996; 347: 1563.
71. Enders G, Dotsch J, Bauer J, Nutzenadel W, Hengel H, Haffner D, Schalasta G, Searle K, Brown KE. Life-threatening parvovirus B19-associated myocarditis and cardiac transplantation as possible therapy: two case reports. Clin Infect Dis 1998; 26: 355-8.
72. Heegaard ED, Eiskjaer H, Baandrup U, Hornsleth A. Parvovirus B19 infection associated with myocarditis following adult cardiac transplantation. Scand J Infect 1998; 30: 607-10.
73. Lower FE, Menon S, Sanchez JA. Association of parvovirus B 19 with plasma cell-rich myocardial infiltrates after heart transplantation. J Heart Lung Transplant 2001; 20: 755-8.
74. Moffatt S, Tanaka N, Tada K, Nakamura M, Murakoa O, Hirano T, Sagamura K. A cytotoxic non-structural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J Virol 1996; 70: 8484-91.
75. Magro CM, Dawood MR, Crowson AN. The cutaneous manifestations of human parvovirus B19 infection. Hum Pathol 2000; 31: 488-97.
76. Corman LC, Dolson DJ. Polyarteritis nodosa and parvovirus B19 infection. Lancet 1992; 339: 491.
77. Jawad AS. Lupus and parvovirus. Br J Rheumatol 1993; 32: 526.
78. Pouchot J, Ouakil H, Debin ML, Vinceneux P. Adult Still's disease associated with acute human parvovirus B19 infection. Lancet 1993; 341: 1280-1.
79. Nocton JJ, Miller LC, Tucker LB, Schaller JG. Human parvovirus B19-associated arthritis in children. J Pediatr 1993; 122: 186-90.
80. Zakrzewska K, Azzi A, De Biasi E, Radossi P, De Santis R, Davoli PG, Tagariello G. Persistence of parvovirus B19 DNA in synovium of patients with haemophilic arthritis. J Med Virol 2001; 65: 402-7.
81. Brown KE. Haematological consequences of parvovirus B19 infection. Best Pract Res Clin Haematol 2000; 13: 245-59.
82. Heegaard ED, Peterslund NA, Hornsleth A. Parvovirus B19 infection associated with encephalitis in a patient suffering from malignant lymphoma. Scand J Infect Dis 1995; 27: 631-3.
83. Pellas F, Olivares JP, Zandotti C, Delarque A. Neuralgic amyotrophy after parvovirus B19 infection. Lancet 1993; 342: 503-4.
84. Servant A, Laperche S, Lallemand F, Marinho V, De Saint Maur G, Meritet JF, Garbarg-Chenon A. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002; 76: 9124-34.
85. Umene K, Nunoue T. Current molecular epidemiology and human parvovirus B 19 infection. Pathol Biol 2002; 50: 285-94.
86. Anderson LJ, Tsou C, Parker RA, Chorba TL, Wulff H, Tattersall P, Mortimer PP. Detection of antibodies and antigens of human parvovirus B 19 by enzyme linked immunosorbent assay. J Clin Microbiol 1986; 24: 522-6.
87. Kajigaya S, Fujii H, Field A, Anderson S, Rosenfeld S, Anderson LJ, Shimada T, Young NS. Self-assembled B 19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc Natl Acad Sci USA 1991; 88: 4646-50.
88. Vassias I, Pérol Y, Coulombel L, Thébault MC, Lagrange MC, Morinet F. An in situ hybridization technique for the study of B19 parvovirus replication in bone marrow cell cultures. J Virol Methods 1993; 44: 329-38.
89. Clewley JP. Polymerase chain reaction assay of parvovirus B19 DNA in clinical specimens. J Clin Microbiol 1989; 27: 2647-51.
90. Srivastava A, Lu L. Replication of B19 parvovirus in highly enriched hematopoietic progenitor cells from normal human bone marrow. J Virol 1988; 62: 3059-63.
91. Srivastava C, Zhou S, Munshi NC, Srivastava A. Parvovirus B19 replication in human umbilical cord blood cells. Virology 1992; 189: 456-61.
92. Rosenfeld SJ, Young NS. Viruses and bone marrow failure. Blood Rev 1991; 5: 71-7.
93. Penchansky L, Jordan JA. Transient erythroblastopenia of childhood associated with human herpes virus type 6, variant B. Am J Clin Pathol 1997; 108: 127-32.
94. Tchernia G, Croisille L, Willig TN. Anémie de Blackfan-Diamond: données récentes. Hématologie 2000; 6: 143-9.
95. Croisille L, Tchernia G, Casadevall N. Autoimmune disorders of erythropoiesis. Curr Opin Hematol 2001; 8: 68-73.
96. Fairley CK, Smoleniec JS, Caul OE, Miller E. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection. Lancet 1995; 346: 1335-7.
97. Bansal GP, Halfield JA, Dunn FE, Kramer AA, Brady F, Riggin CH, Collett MS, Yoshimoto K, Kajigaya S, Young NS. Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis 1993; 167: 1034-44.
98. Marchand S, Tchernia G, Hiesse C, Tertian G, Cartron J, Kriaa F, Boubenider S, Goupy C, Lecointe D, Charpentier B. Human parvovirus infection in organ transplant recipients. Clin Transpl 1999; 13: 17-24.
99. Klenerman P, Tolfvenstam T, Price DA, Nixon DF, Broliden K, Oxenius A. T lymphocyte responses against human parvovirus B19: small virus, big response. Pathol Biol 2002; 50: 317-25.
100. Luo W, Astell CR. A novel protein encoded by small RNAs of parvovirus B19. Virology 1993; 195: 448-55.